Valneva SE, a leading specialty vaccine company, has announced the appointment of Dr. Hanneke Schuitemaker, Ph.D., as its new Chief Scientific Officer and Executive Committee member. Dr. Schuitemaker, a renowned expert in the field of vaccine development, will assume her new role effective June 3, 2024.
With an impressive background in virology and immunology, Dr. Schuitemaker brings a wealth of experience to Valneva. Her expertise will be invaluable in guiding the company’s research and development efforts, as well as strengthening its position as a global leader in the vaccine industry.
The appointment of Dr. Schuitemaker reflects Valneva’s commitment to innovation and scientific excellence. As the company continues to develop groundbreaking vaccines, Dr. Schuitemaker’s leadership and strategic vision will play a crucial role in shaping its future success.
